Momenta Pharmaceuticals (NASDAQ:[[ticker:MNTA]]), a Cambridge, MA-based developer of generic and original biotech drugs, reports this morning that it has priced an offering of 4 million shares of its common stock at $10.75 per share. The offering, which is due to close on September 28, is expected to net the company $40.6 million. The stock offering comes as the company continues its years-long wait for the FDA to okay its application to begin sales of its generic version of blood thinner enoxaparin, which French drug giant Sanofi-Aventis markets as Lovenox.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
